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Abstract We analysed 161 patients
with acute migraine in our emer-
gency room (ER) to identify the use
of narcotic analgesics as first-line
treatment. Twenty-four percent of
patients were treated with opioid
analgesics and 76% patients were
treated with non-opioid analgesics.
Pain was completely relieved in
100 (62%) patients, partially
relieved in 50 (31%) patients and
was not relieved in 11 (7%) patients
at the time of discharge. Pain relief
was not related to the use of opi-
oids vs. non-opioids. The treatment
of acute migraine in our ER is in
line with the guidelines of the
Headache Societies and needs fur-
ther improvement.
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Introduction
Migraine is one of the most disabling, chronic disorders
rated by a recent WHO survey [1]. A large number of
these patients are treated in the emergency room (ER) for
acute migraine. ER treatment for acute migraine is high-
ly variable, including various NSAIDs, triptans, phe-
nothiazines, metaclopramide, ergotamines, narcotics and
sometimes a combination of these [2]. The American
These findings were presented in a prelimi-
nary form at the 12th International Headache
Congress at Kyoto, Japan, October 2005
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Academy of Neurology, Canadian Medical Association
and Italian Society for the Study of Headaches have pub-
lished guidelines and recommendations related to the
management of severe migraine in the ER [3–6]. These
guidelines clearly recommend the use of non-narcotics
as first-line agents and the use of narcotics as the last
resort for treatment of severe migraine in the ER. Two
studies from the USA and one study from Canada report-
ed very high use of narcotic analgesics (47.5%, 50.7%
and 59.6% respectively) in the ER for management of
acute migraine [7–9].
No studies are available from Pakistan regarding atti-
tudes toward narcotic use and management of acute
migraine in the ER. Our study aimed to find out whether
practice in a tertiary care hospital ER in Karachi meets
IHS guidelines.
Methods
All patients with acute migraine visiting the ER at the Aga Khan
University were retrospectively reviewed during a three-month
period. Patients with headaches other than migraine and patients
requiring hospitalisation were excluded from the study.
A total of 8300 patients were seen during that period in our
ER. Charts of 239 (2.87%) patients presenting with a primary
complaint of headache at the ER during the study period were
reviewed. One hundred and sixty-one (1.91%) patients with a
diagnosis of acute migraine (IHS criteria) were included in the
study. Charts excluded from the study (n=78) were due to
diagnosis other than migraine, that is subarachnoid haemor-
rhage (n=10), intracerebral haemorrhage (n=7), subdural
haematoma (n=7), meningitis (n=3), sinusitis (n=16), head
trauma (n=25), cluster headaches (n=2), miscodings (n=1),
incomplete records (n=6) and non-availability (n=1). Pain sta-
tus was recorded as complete relief, partial relief or no relief
at time of discharge of patient. This subjective information
was given by the patient and documented by a nurse on the
chart. We did not contact any patients to determine relapses.
Patients were divided into two groups based on opioid usage.
The comparison of different characteristics like gender, relief
status, nausea and vomiting status, and photophobia by type of
analgesic used for treatment using a chi-square test and the
difference in the mean ages of the patient and mean duration
of headache before presentation to ER were analysed using an
independent samples t-test. The software used for analysis was
SPSS (version 13.0).
Results
Out of 161 patients included in study, 103 (64%) were
female. The age range was 18–59 years (mean age=34
years). Associated nausea, vomiting and photophobia
were present in 94 (59%) patients. Mean duration of
headache was 10 h before presentation to ER.
Neurological examination was normal in all patients.
Thirty-nine (24%) patients were treated with opioid anal-
gesics (pethidine, 25; pentazocine, 10; and oral opioid
analgesics, 4) while 122 (76%) patients received non-opi-
oid analgesics (diclofenac, 80; ketorolac, 32; tramadol,
10). No patient received triptans or steroids in the ER.
Fifty-five (35%) patients received injectable anti-emetics,
in addition to analgesic injections. Pain was completely
relieved in 100 (62%) patients, partially relieved in 50
(31%) patients and was not relieved in 11 (7%) patients at
the time of discharge. Pain relief was not related to use of
opioids vs. non-opioids (Table 1).
Table 1 Comparison of patients’ characteristics by type of analgesics used
Variable Opioid analgesics Non-opioid analgesics p-value
Number of patients, n (%) 39 (24) 122 (76)
Average age, years ±SD 30±12 34±15 0.09
Sex, n (%)
Male 14 (36) 44 (36) 0.1
Female 25 (64) 78 (64)
Having nausea, vomiting, n (%) 22 (56) 72 (59) 0.95
Having photophobia or phonophobia, n (%) 14 (36) 51 (42) 0.15
Mean duration of headache before 11 9 0.09
presentation to ER, hours
Relief status, n (%) 0.497
Complete relief 22 (56) 78 (64)
Partial relief 15 (38) 35 (29)
No relief 2 (5) 9 (7)
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Discussion
Less than a quarter of the patients in our study were treat-
ed with opioid analgesics as the first-line therapy for
acute migraine in our ER. These findings are in contrast
to previously published studies from the USA and
Canada. The relatively low use of narcotics is in line with
recommendations by various National Headache
Societies. It could be due to increased awareness among
our ER physicians regarding acute migraine treatment
guidelines. Although these guidelines have been well
published and circulated in the neurology literature, we
believe that most of the ER physicians are not aware of
these guidelines. This awareness may be related to a
workshop that was organised by the Neurology
Department regarding evaluation and management of
acute headache in the ER for emergency physicians about
six months before this study. The Emergency Department
developed guidelines for acute migraine relief in consul-
tation with the Neurology Department after the workshop.
They had been put into place at the time of study. We do
not know the frequency of opioid use for acute migraine
in the ER prior to this workshop and guidelines but it
would be interesting to know whether our guidelines
made a difference. We suggest that guidelines related to
ER management of severe headache or migraine should
be jointly published and circulated by the Society of
Emergency Physicians and Headache and Neurology
Societies. Workshops for acute migraine management in
the ER could be organised for ER physicians highlighting
those guidelines. Despite the training and guidelines, 24%
were still treated with opioid analgesics. We are unable to
identify factors responsible for opioid use for acute
migraine in our ER. This is a limitation of our study. The
possible reasons for opioid use in these patients could be
treatment before final diagnosis of migraine was estab-
lished, allergy or contraindications to non-steroidal use,
previous history of migraine relief with opioids etc.
Acute headache contributed only 3% and acute
migraine only 2% of all ER visits at our hospital. The low
frequency of headache in our ER is probably due to its ter-
tiary care nature and long waiting times for headache
patients. Another interesting observation was that there
was no use of triptans in the ER for acute migraine relief.
There could be many reasons for not using triptans in the
ER, including lack of awareness among ER physicians,
non-availability of subcutaneous triptans, long duration of
headache before presentation, and associated nausea and
vomiting. Subcutaneous triptans are not available in
Pakistan. Only two oral triptans are available in Pakistan:
sumitriptan and zolmitriptan; but awareness regarding the
usefulness of these medications for acute migraine is lim-
ited to neurologists.
We were unable to identify any factors associated with
the use of one or the other medications. The use was most
likely dependent on ER physicians’ preference or experi-
ence. This is probably why wide variations are noted in
terms of choice of medication for treatment of acute,
severe headache in ERs. Our data confirm the previous
findings that opioid analgesics are not superior to non-opi-
oid analgesics for relief of acute migraine.
There are certain limitations to this study. We did not
collect data regarding time of day as predictor of opioid
use, length of stay in ER and relapse rate. This informa-
tion would have benefited the paper. It is extremely hard
to ascertain the exact severity of migraine from a retro-
spective chart review. Prospective studies should use an
analogue scale for quantification of migraine severity. It
may correlate to opioid use in the ER.
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